Commission Report Highlights the Potential of Personalised Medicine

The European Commission has published a report which takes stock of the progress made in the field of personalised medicine and the opportunities and challenges associated with its implementation in a healthcare setting. The report focuses on three main areas: 1) the potential for, and issues with, the use of '-omics' technologies in personalised medicine, and the related EU research funding, 2) recent developments in EU legislation for placing medicinal products and devices on the market, and 3) factors affecting the uptake of personalised medicine in health care systems.

The report concludes that personalised medicine has the potential to offer new treatment opportunities for the benefit of patients, including better targeted treatment, avoiding medical errors and reducing adverse reactions to medicines.

Personalised Medicine should be seen as an evolution of medicine, rather than a revolution, and the report recognises the challenges (e.g. in research) associated with its successful entry in healthcare systems. The European Commission will continue to monitor the developments of personalised medicine in the coming years and maintain a fruitful dialogue with stakeholders.

What is personalised medicine?
Although no official definition of personalised medicine exists, it can best be explained as a medical approach which is tailored to the patient or a group of pati! ents - for prevention, prediction and treatment. In other words, it moves away from the common "one size fits all" medical model.

How does the EU support personalised medicine?
Since 2007 the EU has committed over €1 billion of health research funding underpinning the development of personalised medicine through its Seventh Framework Program for Research and Technological Innovation. Going forward, funding under Horizon 2020, the EU's new framework program to be launched at the end of this year, will continue to support this field.

A constructive legal framework has also contributed to the development of personalised medicine. The regulatory framework for pharmaceuticals offers a number of tools and procedures to ensure that medicines placed on the market are of high quality, safety and efficacy. These tools, complemented by scientific guidelines and expert evaluation, have already worked well for innovative products including therapies relevant to personalised medicine.

The ongoing revisions of important pieces of legislation address certain challenges identified in the development of these therapies. The revision of the medical devices legislation will strengthen the legal framework of in vitro diagnostics and introduce a better consultation process for companion diagnostics to assess patient eligibility for treatment with a specific medicinal product. The revision of the Clinical Trials Directive is expected to simplify the conduct of clinical trials and consequently facilitate research in therapies using personalised medicine.

Finally, EU-level cooperation on Health Technology Assessment can help Member States assess the value of using personalised medicine in their health systems, i.e. judge whether their benefits will offset their costs through efficiency gains.

Download: Use of '-omics' technologies in the development of personalised medicine (.pdf, 258 KB).

Download from eHealthNews.eu Portal's mirror: Use of '-omics' technologies in the development of personalised medicine (.pdf, 258 KB).

Most Popular Now

Artificial Intelligence Solution Improve…

Clinical trials are a critical tool for getting new treatments to people who need them, but research shows that difficulty finding the right volunteer subjects can undermine the effectiveness of...

South West London Pathology Picks CliniS…

One of the first pathology networks in the country, set up to serve more than two million people in south west London, has signed a contract with CliniSys for a...

Call for Tenders: Studies on eHealth, In…

The European Commission is launching a tender for two studies to survey and analyse progress on the digital transformation of the health and care in the EU, in particular with...

AI-based AI-Rad Companion Chest CT Softw…

AI-Rad Companion Chest CT(1), an intelligent software assistant for radiology, was recently awarded the CE mark, which means Siemens Healthineers can start marketing this artificial intelligence (AI)-based software as a...

Spot On for Healthcare Technology Startu…

10 - 12 October 2019, Berlin, Germany. XPOMET Medicinale brings together care providers, patients, and in general stakeholders from all health-related fields and geographic regions. The Festival of Future Medicine and...

Isansys Named as Finalist for OBN's Most…

Isansys Lifecare is proud to announce it has been shortlisted in the Most Transformative Digital Healthcare Company category at the OBN Annual Awards 2019. The award recognises the significant uptake...

7th MEDICA MEDICINE + SPORTS CONFERENCE

18 - 21 November 2019, Düsseldorf, Germany. What lengths do top athletes go to in order to reach peak performances and which findings in the field of professional sports are relevant...

How can We Successfully Converge the Hea…

Opinion Article by Erik Janssen, VP, Innovative Solutions, Neurology, UCB Pharma. The fourth industrial revolution is upon us and fundamentally changing the way we live, work and interact across all industries...

Carestream Health Completes Sale of Heal…

Carestream Healthhas completed the sale of the company's healthcare information solutions business to Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, in 26 of the 38...

Allscripts Listed on Lot One of Health S…

Allscripts has been included on a new list of accredited suppliers of electronic patient records that has been published by NHS England and NHSX. The company is one of just...